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Purpose: Anticholinergics are a key element in treating neurogenic detrusor over-
activity, but only limited data are available in the pediatric population, thus limiting 
the application to children even for oxybutynin chloride (OC), a prototype drug. This 
retrospective study was designed to provide data regarding the efficacy, tolerability, 
and safety of OC in the pediatric population (0–15 years old) with spinal dysraphism 
(SD).
Materials and Methods: Records relevant to OC use for neurogenic bladder were gath-
ered and scrutinized from four specialized clinics for pediatric urology. The primary 
efficacy outcomes were maximal cystometric capacity (MCC) and end filling pressure 
(EFP). Data on tolerability, compliance, and adverse events (AEs) were also analyzed.
Results: Of the 121 patient records analyzed, 41 patients (34%) received OC at less than 
5 years of age. The range of prescribed doses varied from 3 to 24 mg/d. The median treat-
ment duration was 19 months (range, 0.3–111 months). Significant improvement of 
both primary efficacy outcomes was noted following OC treatment. MCC increased 
about 8% even after adjustment for age-related increases in MCC. Likewise, mean EFP 
was reduced from 33 to 21 cm H2O. More than 80% of patients showed compliance above 
70%, and approximately 50% of patients used OC for more than 1 year. No serious AEs 
were reported; constipation and facial flushing consisted of the major AEs.
Conclusions: OC is safe and efficacious in treating pediatric neurogenic bladder asso-
ciated with SD. The drug is also tolerable and the safety profile suggests that adjust-
ment of dosage for age may not be strictly observed.
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INTRODUCTION
About 0.6 to 4 newborn children per 1,000 suffer from spinal 
dysraphism (SD). This can be characterized by incomplete 
development of the central nervous system, which includes 
open (myelocele and meningomyocele) or closed (lipoma, 
occult spina bifida, and dermal sinus) entities [1,2]. 
Frequently, the above-mentioned anomalies are compli-
cated by neurogenic bladder dysfunction and detru-
sor-sphincter dysfunction, represented by urinary incon-
tinence, urinary tract infection, and deterioration of the up-
per urinary tract [3,4]. Clean intermittent catheterization 
and anticholinergic drugs have been accepted as con-
servative measures to alleviate these problems [5].
Anticholinergic agents inhibit the binding of acetylcho-
line to the cholinergic receptors (thereby inhibiting in-
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TABLE 1. Demographics and clinical data of study population
Parameter Value
Spinal dysraphism 
Open (myelocele and meningomyelocele)
Closed (occult spina bifida including spinal 
lipoma) 
Sex 
Male
Female
Age at treatment with OC (y)
0–5 
6–10 
11–15 
Median (range)
Pretreatment urodynamic diagnosis 
Detrusor overactivity with synergic urethra 
Detrusor overactivity with dyssynergic 
urethra
Final prescribed dosage (mg/d)
3–5 
5–10 
11–15 
＞15 
Updosing
Duration of drug treatment 
＜3 mo
3 mo–1 yr
1–3 yr
＞3 yr
Median (range)
Compliance (%)
＜50
50–70
70–100
 
39 (32)
82 (68)
 
58 (48)
63 (52)
 
41 (34)
37 (31)
43 (35)
8 (1–15)
 
16 (13)
105 (87) 
 
4 (3)
89 (74)
19 (16)
9 (7)
20 (17)
 
12 (10)
42 (35)
39 (32)
28 (23)
19 (0.3–111)
 
4 (3)
16 (13)
101 (84) 
Values are presented as number (%) unless otherwise indicated.
OC, oxybutynin chloride.
voluntary bladder contractions), increase the volume at 
which the first involuntary bladder contraction occurs, re-
duce intravesical pressure, and may increase total bladder 
capacity [6-8]. Common safety concerns for anticholinergic 
drugs relate to decreased secretory function (dry mouth, 
constipation), reduced smooth muscle contraction (consti-
pation and acute urinary retention), and untoward effects 
on the central nervous system. 
Recent years have seen several newly developed anti-
cholinergics be applied for the treatment of neuropathic 
bladder. However, most data were focused on the treat-
ment of adults and only a small number of data are avail-
able for children. So far, oxybutynin, tolterodine, propiver-
ine, and solifenacin have been applied to children, but not 
often enough to warrant their use in terms of safety and 
efficacy. In Korea, only oxybutynin is accepted for children 
over 5 years of age, thus limiting the choice for adequate 
anticholinergics for children. Thus, more evidence in chil-
dren should be obtained to loosen the restrictions on anti-
cholinergic use. Thus, we analyzed our data on the 
long-term safety, tolerability, and efficacy of oxybutynin 
chloride (OC) in children with SD to provide more in-
formation for the current database. 
MATERIALS AND METHODS
The terminology and definitions in this paper comply with 
the 2006 standardization report of the International 
Children’s Continence Society [9]. After obtaining permis-
sion from the Ethical Review Board, four institutions took 
part in this study, all of which have multidisciplinary 
teams for children with SD. These children are seen on reg-
ular basis depending on age and clinical course, but at least 
once yearly. The patient database was scrutinized for chil-
dren and adolescents meeting the selection criteria of hav-
ing neurogenic detrusor overactivity due to SD, having 
been allocated to treatment with oxybutynin, and having 
been prescribed oxybutynin at less than 15 years of age. In 
all patients, the diagnosis of neurogenic detrusor over-
activity had been proven by history and urodynamic 
assessment. Detrusor overactivity was defined as unin-
hibited detrusor contractions of 15 cm H2O or greater. 
Intermittent catheterization was performed in those who 
showed dyssynergic sphincter.
The primary efficacy outcome parameters, maximal cys-
tometric capacity (MCC) and end filling pressure (EFP), 
i.e., peak detrusor pressure at capacity, were evaluated be-
fore and during OC treatment. With regard to MCC, effects 
subsequent to OC treatment and effects attributable to the 
age-related increase in capacity had to be adjusted for. 
Therefore, the individual MCC was calculated as a percent-
age of expected age-adjusted capacity according to the for-
mula proposed by Hjalmas [10].
The second efficacy parameters were the compliance as-
sessed during cystometry and the number of incontinence 
episodes assessed from the information given by the pa-
rents and their caregivers. While the reference value was 
defined before OC medication, during-treatment values 
were assessed at the last available urodynamic inves-
tigation during OC treatment. Thus, the conditions and 
time intervals between reference and during treatment 
varied widely in each patient. 
Other important variables during long-term treatment 
were tolerability, compliance, and safety issues. We meas-
ured total days of OC treatment and compliance when rele-
vant data were available. Adverse events (AEs), mentioned 
in the patient’s file or reported by patients or their care-
givers during the follow-up visits, were also documented.
For statistical analysis of the efficacy and safety parame-
ters, the paired t-test and chi-square test were applied. The 
level of statistical significance was set at p=0.05. 
RESULTS 
Owing to the retrospective nature of this observational, un-
controlled study, some data for the different parameters 
were missing to various extents. Of the 385 files for pedia-
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FIG. 1. Comparison of maximal cystometric capacity (A), age 
adjusted maximal cystometric capacity (B), and end filling 
pressure (C) between pretreatment and posttreatment with 
oxybutynin chloride. Each value represents mean±standard
deviation. *p＜0.05. **p＜0.01.
tric patients, 121 files of neurogenic detrusor overactivity 
owing to SD were eligible for review (87 in center one, 22 
in center two, 4 in center three, and 8 in center four). No 
significant differences in demographic data were noted be-
tween those who were included and those who were ex-
cluded from this study. The demographic data and clinical 
parameters of the patients are given in Table 1. A larger 
number of closed SD cases than the open type were 
included. The median age at treatment was 8 years (range, 
1–15 years). Forty-one patients (34%) received OC at less 
than 5 years of age.
OC was prescribed as a first anticholinergic treatment 
in all patients. Also, it was confirmed that no medication 
or treatment other than OC was given for sphincter or de-
trusor function before or during treatment. The prescribed 
dose of OC was adjusted individually at the discretion of 
investigators and varied from 3 to 24 mg/d. 
Although patients who were not able to swallow the tab-
let were treated with immediate-release OC prescribed in-
to syrup, those over 5 years of age who were able to swallow 
the tablet were prescribed the extended-release form of OC 
(5–15 mg/d). Whereas 69 patients (57%) used less than 5 
mg of OC, 50 patients (41%) used at least 10 mg of OC a day. 
Up-dosing was reported in 20 patients (17%) owing to in-
sufficient efficacy. The median treatment duration was 19 
months (range, 0.3–111 months).
1. Efficacy 
The primary urodynamic parameters, MCC and EFP, were 
improved significantly following OC treatment (Fig. 1). 
This improvement in MCC was maintained even after we 
adjusted for age-related increases in bladder capacity. The 
mean percentages of the expected age-adjusted capacities 
were still significantly increased by 8% (Wilcoxon singed 
rank test) even after this adjustment. Compared to pre-
treatment values, 65 (53%) and 31 (26%) achieved improve-
ment and normalization of adjusted bladder capacity, re-
spectively, following OC treatment.
Mean pretreatment EFP was 33 cm H2O, and 51 patients 
(42%) showed a mean EFP of more than 40 cm H2O. 
Following treatment, mean EFP was reduced to 21 cm H2O 
and in 19 patients (16%) the value was still more than 40 
cm H2O. 
As secondary efficacy parameters, bladder compliance 
and global assessment of incontinence were compared (Fig. 
2). A significant increase in bladder compliance was seen 
after OC treatment. OC markedly improved the control of 
incontinence. Approximately 90% reported that the medi-
cation helped the control of incontinence. 
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TABLE 2. Adverse events occurred following medication with 
oxybutynin chloride
Adverse events
No. 
(%)
Severity (n)
No. of leading to 
discontinuation (%)
Dry mouth
Constipation
Poor feeding 
Facial flushing
Voiding difficulty 
Drowsiness
1 (1)
8 (7)
1 (1)
4 (3)
1 (1)
2 (2)
Mild (1)
Mild (5), 
moderate (3) 
Mild (1)
Mild (3), 
moderate (1)
Mild (1)
Mild (2)
-
4 (3)
-
-
-
2 (2)
FIG. 2. The second efficacy parameters are depicted. Changes of bladder compliance (A) and incontinence status following the 
treatment of oxybutynin chloride (B) are seen.
2. Tolerability and safety
Overall compliance for OC was good; 101 patients (82%) 
showed more than 70% compliance. OC was tolerable in 
most patients. The mean duration of treatment with OC 
was 576 days (range, 30–3,330 days). Only 22 patients 
(18%) took OC for less than 90 days and approximately 50% 
of patients used OC for more than 1 year. OC was taken for 
more than 3 years in 20 patients (17%). Of those who dis-
continued the OC in less than 90 days, inadequate treat-
ment response and AEs were responsible for early dis-
continuation in 16 (72%) and 6 patients (28%), respectively.
The reported AEs are described in Table 2. No AEs were 
seen in 104 patients (85%). Constipation and facial flush-
ing consisted of the major AEs. Of the 6 AEs that led to dis-
continuation of OC, constipation was responsible in 4 cases 
and dizziness in 2. No serious AEs were documented.
DISCUSSION 
In this study, we collected and analyzed data from several 
large institutions in Korea to demonstrate the efficacy, tol-
erability, and safety of OC in pediatric patients with SD. 
Although the limited number of patients in our data set pre-
vented us from drawing definite conclusions about efficacy 
and safety, our data revealed that OC was efficacious, safe, 
and tolerable in pediatric patients, as in adults. Of note, the 
fact that about one-third of the patients treated with OC 
were less than 5 years of age suggested that OC may be tol-
erable and safe at these ages for which the use of OC is not 
approved. This is consistent with a previous report showing 
good efficacy profiles in children aged less than 5 years 
without any increase in AEs [11].
OC was the first anticholinergic used in all patients. This 
was because no anticholinergics other than OC are ap-
proved for use in the pediatric population in Korea. 
Because our data demonstrated the benefit and safety of 
OC in children, it is expected that other anticholinergics 
may also be useful in children. Previous studies have al-
ready shown the efficacy and safety of other anti-
cholinergics such as tolterodine [12] and propiverine [8].
One interesting finding that should be mentioned was 
that the dosages used were comparable to those for adults. 
Ninety percent of treated patients received 5 to 15 mg of 
OC, which is comparable to the 86.5% reported previously 
for Korean adults [13]. Although this study was conducted 
in patients with neurogenic bladder, which often requires 
higher doses of anticholinergics for treatment than does 
the nonneurogenic type [14], the finding that higher dos-
ages of OC can be used in children may be additional sup-
porting evidence for the tolerability and safety of OC in the 
pediatric population. This is consistent with the claim that 
comparatively high doses of anticholinergics can be used 
in children [15].
Like previous reports of OC in the pediatric population, 
the clinical efficacy of OC in neurogenic detrusor over-
activity was documented in this study by significant im-
provements in all primary efficacy outcome parameters. In 
particular, MCC was increased even after adjustment for 
the age-related physiological increase. The effects attrib-
uted to OC, which were calculated following adjustment for 
the age-related increase in bladder capacity, demonstrated 
a significant increase of 8%. We believe that this increase 
is meaningful given the fact that the normal values for blad-
der capacity were set from the data of healthy controls of 
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the same age [10]. Consequently, about one-half and 
one-third of the patients achieved improved and normal-
ized bladder capacity following treatment, respectively. 
Reduction of EFP is expected to preserve the upper uri-
nary tract with regard to renal insufficiency. Following 
treatment with OC, mean EFP decreased and about 30% 
of patients with an EFP over 40 cm H2O before treatment 
experienced the conversion of their EFP into the safe range.
About 90% of patients reported that their incontinence 
improved after treatment, but only 38% reported complete 
control. Because OC improved incontinence by reducing 
detrusor overactivity and increasing compliance, this im-
provement was not unexpected. The failure of complete 
control of incontinence may be related to inadequate dos-
ing, the concomitant presence of sphincteric incompetence, 
or an insufficient number of OC to control incontinence.
We believe that tolerance reflects the real-world status 
of drug safety, although other reasons may affect it. Over 
80% showed good tolerance and about one-half of the pa-
tients took OC for more than 1 year, which is comparable 
to the tolerance profile reported in adults.
The main concern for use of anticholinergics in pediatric 
populations is a higher occurrence of AEs in children and 
more severe AEs than in adults and the possible occurrence 
of side effects related to the central nervous system. Our 
data contradicted this concern. Constipation and facial 
flushing of mild to moderate severity were the main side 
effects of OC in treated children. Because constipation is 
inherent to this population owing to the neurogenic bowel 
problem, a much small number was affected by con-
stipation attributed to OC. Only facial flushing was the 
main AE from OC use. Compared with the high incidence 
of dry mouth in adults, no significant episode was realized 
[16]. The occurrence of AEs likely to be related to the central 
nervous system consisted of only 2 cases of dizziness. 
Although the severity was not reported to be significant, 
this led these patients to quit the medication. Assuming 
that the low incidence of AEs may be related to insufficient 
inquiry in the real-world situation, it would be safe to say 
that OC was acceptable in pediatric neurogenic bladder 
with SD. Also, our data may help to expand the indication 
for OC in children and prompt more studies of anti-
cholinergics in children for their approval in Korea. 
Despite the availability of several anticholinergics for the 
adult population, only OC is approved in children over 5 
years of age in Korea, thus limiting the beneficial effect of 
anticholinergics in children. The necessity for expanding 
the indication for anticholinergics was reflected by the un-
equal distribution of enrolled patients with regard to each 
hospital. Although all four hospitals were believed to have 
a comparable number of patients with SD, the enrolled 
number for each hospital was quite different, implying a 
lower preference for OC in the clinical practices of some 
centers. These practices seem to have treated the patients 
with other anticholinergics by off-label use, realizing the 
limitation of OC in treating this kind of patient. The fact 
that the main reason for quitting OC was insufficient re-
sponse rather than AEs should be born in mind. In this re-
gard, increased use of anticholinergics other than OC to 
achieve better response in real practice is a natural ten-
dency for clinicians despite the risk of off-label use.
The limitations of this study should be mentioned. This 
was an observational, retrospective, and descriptive study 
without a control group. As a result, the efficacy and safety 
of each patient was not measured on the same time scale, 
precluding drawing definite conclusions. This explained 
why we did not analyze the data in the voiding diaries. In 
addition, a substantial number of patients were excluded 
from this study owing to a lack of comparable urodynamic 
data, which is inherent in a retrospective, real-world clin-
ical study. 
An additional potentially significant limitation is that 
we did not check the presence of constipation. However, we 
were not able to examine this owing to the retrospective na-
ture of our study and the lack of an effective diagnostic tool. 
Although the population treated with OC was not small, 
the wide age range may not allow us to obtain sufficient in-
formation regarding safety for all age ranges. Nonetheless, 
the large number of patients, the multicenter design, and 
the detailed information on tolerability may add valuable 
information to our current knowledge for the widespread 
use of OC.
CONCLUSIONS
This retrospective observational study showed that OC is 
safe and efficacious in treating pediatric neurogenic blad-
der caused by SD. The drug is also tolerable and the safety 
profile was not worrisome on the basis of the prevalence and 
severity of reported AEs.
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